As of 2026-06-18, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is (5.65) USD. This relative valuation is based on P/E multiples. With the latest stock price at 43.58 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -113.0%.
The range of the Relative Valuation is (3.94) - (5.86) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 11.7x | 9.2x |
| Forward P/E multiples | 7.9x - 18.3x | 13.4x |
| Fair Price | (3.94) - (5.86) | (5.65) |
| Upside | -109.0% - -113.4% | -113.0% |
| Date | P/E |
| 2026-06-16 | -87.17 |
| 2026-06-15 | -87.73 |
| 2026-06-12 | -88.83 |
| 2026-06-11 | -91.11 |
| 2026-06-10 | -90.19 |
| 2026-06-09 | -91.33 |
| 2026-06-08 | -88.97 |
| 2026-06-05 | -89.51 |
| 2026-06-04 | -89.41 |
| 2026-06-03 | -88.08 |
| 2026-06-02 | -88.15 |
| 2026-06-01 | -89.53 |
| 2026-05-29 | -92.37 |
| 2026-05-28 | -93.71 |
| 2026-05-27 | -93.29 |
| 2026-05-26 | -95.55 |
| 2026-05-22 | -96.43 |
| 2026-05-21 | -98.77 |
| 2026-05-20 | -97.39 |
| 2026-05-19 | -95.25 |
| 2026-05-18 | -96.67 |
| 2026-05-15 | -98.87 |
| 2026-05-14 | -102.41 |
| 2026-05-13 | -102.73 |
| 2026-05-12 | -101.07 |
| 2026-05-11 | -98.75 |
| 2026-05-08 | -103.07 |
| 2026-05-07 | -104.57 |
| 2026-05-06 | -102.91 |
| 2026-05-05 | -98.39 |
| 2026-05-04 | -97.27 |
| 2026-05-01 | -95.71 |
| 2026-04-30 | -96.01 |
| 2026-04-29 | -97.11 |
| 2026-04-28 | -97.39 |
| 2026-04-27 | -98.93 |
| 2026-04-24 | -99.53 |
| 2026-04-23 | -100.79 |
| 2026-04-22 | -100.59 |
| 2026-04-21 | -98.25 |
| 2026-04-20 | -102.51 |
| 2026-04-17 | -102.79 |
| 2026-04-16 | -98.45 |
| 2026-04-15 | -99.89 |
| 2026-04-14 | -100.23 |
| 2026-04-13 | -99.91 |
| 2026-04-10 | -101.37 |
| 2026-04-09 | -103.01 |
| 2026-04-08 | -103.23 |
| 2026-04-07 | -101.93 |